Based on our results, we recommend integrating the detection of CRP-associated, circulating platelet-derived, endothelial cell-derived, and monocyte-derived EVs, along with plasma CPN1 concentrations, into the CAD diagnostic/prognostic panel as supportive biomarkers. This evidence concerns the gene CPN1 and coronary artery disorder.